Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377418 | 0.73 | MAOA (0.46) | MAOAMAOBATM | |
| SCHEMBL5326093 | 0.73 | MAOA (0.37) | MAOAMAOBATM | |
| SCHEMBL3373132 | 0.73 | MAOA (0.37) | MAOAMAOBATM | |
| SCHEMBL4911794 | 0.70 | MAOA (0.34) | MAOAMAOB | |
| SCHEMBL11502045 | 0.70 | LMNA (0.37) | MAOAMAOB | |
| SCHEMBL4723880 | 0.68 | GPR3 (0.38) | MAOAMAOB | |
| SCHEMBL11227302 | 0.68 | MAOA (0.33) | MAOAMAOB | |
| SCHEMBL4723691 | 0.68 | PDPK1 (0.36) | MAOAMAOB | |
| SCHEMBL925300 | 0.68 | HTR2C (0.34) | MAOAMAOB | |
| SCHEMBL1038844 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| EP-2134714-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | Biovitrum AB (publ) (SE) | 2009-12-23 | — | — | EP | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| WO-2008110598-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | BIOVITRUM AB (PUBL) (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293694-A1 | New compounds | HTR6, HTR1A, HTR1B | MAOA 187/4885MAOB 135/4885ATM 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.